Free tool
Cell therapy stocks
We cover 42 companies grouped under the Cell therapy theme. The median market value in the group is $30.38M. Across the group, the median move over the past trading day is −0.20%. 21% of the 42 with a 200-day average trade above it. Price change over the past year runs from −85.9% to −9.5% across the middle 80 percent of the group, with a median of −42.4%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
42 of 86 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return |
|---|---|---|---|---|---|
| ATRA | Atara Biotherapeutics, Inc. | $9.38 | +20.10% | −47.21% | −24.05% |
| ACET | Adicet Bio, Inc. | $8.95 | +9.15% | +1.47% | −26.01% |
| INKT | MiNK Therapeutics, Inc. | $11.79 | +11.86% | +6.03% | −26.22% |
| V3V.DE | FamiCord AG | 2.86 EUR | +0.70% | −52.73% | −61.35% |
| 7776.T | CellSeed Inc. | 232.00 JPY | +15.42% | −16.85% | −47.39% |
| 4896.T | K Pharma,Inc. | 763.00 JPY | +6.71% | +13.88% | +14.56% |
| 4584.T | Kidswell Bio Corporation | 179.00 JPY | +29.71% | −15.57% | −26.03% |
| HEMO.L | Hemogenyx Pharmaceuticals Plc | 588.00 GBP | −8.12% | +3.52% | +70.43% |
| ALA.AX | Arovella Therapeutics Limited | 0.06 AUD | −1.59% | −33.33% | −30.34% |
| TCRX | TScan Therapeutics, Inc. | $0.78 | +0.44% | −23.78% | −58.43% |
| 7096.T | StemCell Institute Inc. | 762.00 JPY | +6.87% | −3.30% | −22.80% |
| 2370.T | MEDINET Co., Ltd. | 26.00 JPY | 0.00% | −10.34% | −33.33% |
| TVGN | Tevogen Inc. | $6.70 | +19.86% | −63.19% | −85.43% |
| 3750.T | ADR Biomedical Holdings Inc. | 785.00 JPY | +0.26% | −8.08% | −14.11% |
| 4880.T | CellSource Co., Ltd. | 345.00 JPY | +9.87% | −13.75% | −42.78% |
| 4893.T | Noile-Immune Biotech Inc. | 148.00 JPY | +11.28% | +10.45% | −16.38% |
| 4892.T | Cyfuse Biomedical K.K. | 566.00 JPY | +14.34% | −6.75% | −9.00% |
| PTG.WA | Poltreg S.A. | 25.00 PLN | +9.17% | −1.96% | −14.68% |
| CCEL | Cryo-Cell International, Inc. | $4.25 | +25.74% | +23.91% | −3.19% |
| ESLA | Estrella Immunopharma, Inc. | $0.73 | −2.54% | −47.48% | −22.34% |
| PSH0.DE | Sernova Biotherapeutics Inc | 0.08 EUR | +14.41% | −2.99% | −27.68% |
| SVA.TO | Sernova Biotherapeutics Inc | 0.11 CAD | −8.33% | −15.38% | −42.11% |
| LGVN | Longeveron Inc. | $0.70 | +17.02% | +18.60% | −14.44% |
| 311A.T | NPT Co Ltd | 680.00 JPY | 0.00% | −2.86% | −43.33% |
| NCEL | NewcelX Ltd. | $3.38 | −2.87% | +61.72% | −84.77% |
| BCDA | BioCardia, Inc. | $1.19 | +52.56% | −6.30% | −38.66% |
| PLUR | Pluri Inc. | $1.48 | −11.90% | −50.50% | −69.17% |
| SNTI | Senti Biosciences Holdings, Inc. | $0.39 | +1.15% | −64.87% | −75.23% |
| INAB | IN8bio, Inc. | $1.19 | +6.76% | −51.83% | −48.03% |
| GDTC | CytoMed Therapeutics Limited | $1.00 | +10.13% | −28.29% | −50.41% |
| F98.F | CytoMed Therapeutics Limited | 0.84 EUR | +12.08% | −73.06% | −50.30% |
| FBLG | FibroBiologics, Inc. | $1.41 | +116.92% | −70.62% | −88.25% |
| CMB.AX | Cambium Bio Limited | 0.42 AUD | −2.33% | −9.68% | −4.55% |
| CELZ | Creative Medical Technology Holdings, Inc. | $1.19 | +61.60% | −39.59% | −63.27% |
| 1AD.AX | AdAlta Limited | 0.00 AUD | −25.00% | −25.00% | −25.00% |
| PMCB | PharmaCyte Biotech, Inc. | $0.54 | −8.39% | −26.76% | −44.28% |
| ERNA | Ernexa Therapeutics Inc. | $4.89 | +35.46% | −83.14% | −85.93% |
| BRTX | BioRestorative Therapies, Inc. | $0.22 | −18.64% | −82.22% | −86.10% |
| MBIO | Mustang Bio, Inc. | $0.56 | −11.25% | −47.66% | −63.40% |
| BSFA.L | BSF Enterprise Plc | 1.15 GBP | +43.75% | −39.47% | −48.89% |
| CYP.AX | Cynata Therapeutics Limited | 0.01 AUD | −8.33% | −96.90% | −94.50% |
| CHM.AX | Chimeric Therapeutics Limited | 0.01 AUD | −76.74% | −95.00% | −96.67% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.